According to a research report published this morning, Brean Murray Carret & Co. has upgraded Vertex Pharmaceuticals VRTX from Hold to Buy.
In the report, Brean Murray Carret & Co. said, "Vertex put lackluster Phase 2 results from last summer in the rearview mirror today by demonstrating profound clinical benefits in a subset of cystic fibrosis patients. We believe these results have the potential to expand the company's targeted CF population by 10x. Although Phase 3 still remains a hurdle, we now have confidence that the robust sales numbers seen in the first quarter of Kalydeco sales will be possible across a much larger patient population with the addition of a CFTR corrector (VX-809) to a CFTR potentiator (Kalydeco).Although the true market potential is difficult to gauge at this point, we believe a reasonable penetration into the F508del homozygotes could yield peak WW sales of ~$4 billion."
Brean Murray Carret & Co. maintains its $69 PT on Vertex, which closed yesterday at $57.02.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in